ArticleJournal of molecular histology2026
Identification and validation of GNA15 as a novel diagnostic biomarker in ulcerative colitis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite advances in transcriptomic profiling, reliable diagnostic biomarkers that accurately reflect disease activity and recurrence in ulcerative colitis (UC) remain limited. This study aimed to identify and validate new biomarkers associated with UC. Candidate genes were identified through the intersection analysis of DEGs from the GSE59071 and GSE53306 datasets, weighted gene co-expression network analysis hub genes, and inflammatory response-related genes. Based on this approach, diagnostic biomarkers were selected using least absolute shrinkage and selection operator (LASSO) logistic regression and support vector machine recursive feature elimination (SVM-RFE) algorithms. Diagnostic biomarkers were validated by quantitative real-time polymerase chain reaction, immunohistochemistry, and western blotting. G protein subunit alpha 15 (GNA15) was identified as a new biomarker associated with UC disease activity. Its expression was positively correlated with 24 types of infiltrating immune cells and with the modified Mayo score. GNA15 was upregulated in UC intestinal mucosal samples compared to the control samples. In addition, GNA15 was an independent risk factor associated with UC (odds ratio [OR], 1.225, 95% CI: 1.075–1.397, p = 0.002). The area under the ROC curve for GNA15 protein expression in predicting UC patients was 0.898 (95% CI: 0.786–0.988, p < 0.001). Furthermore, GNA15 expression was significantly increased in dextran sulfate sodium-induced mouse colitis. GNA15 may serve as a new diagnostic biomarker for assessing UC.
Indexed as
Identifiers
41870743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.